tetano
Editor, Senior Moderator
J Clin Med
. 2024 May 21;13(11):3029.
doi: 10.3390/jcm13113029. Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review
Dimitrios Papagiannis[SUP] 1 [/SUP], Christos Kourek[SUP] 2 [/SUP], Alexandros Briasoulis[SUP] 3 [/SUP], Evangelos C Fradelos[SUP] 4 [/SUP], Evangelia D Papagianni[SUP] 5 [/SUP], Ilias Papadimopoulos[SUP] 6 [/SUP], Grigorios Giamouzis[SUP] 7 [/SUP], John Skoularigis[SUP] 7 [/SUP], Andrew Xanthopoulos[SUP] 7 [/SUP]
Affiliations
Background/Objectives: As heart failure (HF) patients face increased vulnerability to respiratory infections, optimizing pneumococcal and influenza vaccination coverage becomes pivotal for mitigating additional health risks and reducing hospitalizations, morbidity, and mortality rates within this population. In this specific subpopulation of patients, vaccination coverage for pneumococcal and influenza holds heightened significance compared to other vaccines due to their susceptibility to respiratory infections, which can exacerbate existing cardiovascular conditions and lead to severe complications or even death. However, despite the recognized benefits, vaccination coverage among HF patients remains below expectations. The aim of the present systematic review was to assess the vaccination coverage for influenza and pneumococcus in HF patients from 2005 to 2023 and the vaccination's effects on survival and hospitalizations. Methods: The authors developed the protocol of the review in accordance with the PRISMA guidelines, and the search was performed in databases including PubMed and Scopus. After the initial search, 851 studies were found in PubMed Library and 1961 in Scopus (total of 2812 studies). Results: After the initial evaluation, 23 publications were finally included in the analysis. The total study population consisted of 6,093,497 participants. Regarding the influenza vaccine, vaccination coverage ranged from low rates of 2.5% to very high rates of 97%, while the respective pneumococcal vaccination coverage ranged from 20% to 84.6%. Most studies demonstrated a beneficial effect of vaccination on survival and hospitalizations. Conclusions: The present systematic review study showed a wide variety of vaccination coverage among patients with heart failure.
Keywords: heart failure; immune system; influenza; pneumococcal disease; vaccination; vaccination coverage.
. 2024 May 21;13(11):3029.
doi: 10.3390/jcm13113029. Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review
Dimitrios Papagiannis[SUP] 1 [/SUP], Christos Kourek[SUP] 2 [/SUP], Alexandros Briasoulis[SUP] 3 [/SUP], Evangelos C Fradelos[SUP] 4 [/SUP], Evangelia D Papagianni[SUP] 5 [/SUP], Ilias Papadimopoulos[SUP] 6 [/SUP], Grigorios Giamouzis[SUP] 7 [/SUP], John Skoularigis[SUP] 7 [/SUP], Andrew Xanthopoulos[SUP] 7 [/SUP]
Affiliations
- PMID: 38892740
- PMCID: PMC11172599
- DOI: 10.3390/jcm13113029
Background/Objectives: As heart failure (HF) patients face increased vulnerability to respiratory infections, optimizing pneumococcal and influenza vaccination coverage becomes pivotal for mitigating additional health risks and reducing hospitalizations, morbidity, and mortality rates within this population. In this specific subpopulation of patients, vaccination coverage for pneumococcal and influenza holds heightened significance compared to other vaccines due to their susceptibility to respiratory infections, which can exacerbate existing cardiovascular conditions and lead to severe complications or even death. However, despite the recognized benefits, vaccination coverage among HF patients remains below expectations. The aim of the present systematic review was to assess the vaccination coverage for influenza and pneumococcus in HF patients from 2005 to 2023 and the vaccination's effects on survival and hospitalizations. Methods: The authors developed the protocol of the review in accordance with the PRISMA guidelines, and the search was performed in databases including PubMed and Scopus. After the initial search, 851 studies were found in PubMed Library and 1961 in Scopus (total of 2812 studies). Results: After the initial evaluation, 23 publications were finally included in the analysis. The total study population consisted of 6,093,497 participants. Regarding the influenza vaccine, vaccination coverage ranged from low rates of 2.5% to very high rates of 97%, while the respective pneumococcal vaccination coverage ranged from 20% to 84.6%. Most studies demonstrated a beneficial effect of vaccination on survival and hospitalizations. Conclusions: The present systematic review study showed a wide variety of vaccination coverage among patients with heart failure.
Keywords: heart failure; immune system; influenza; pneumococcal disease; vaccination; vaccination coverage.